Advanced Magnetics' GastroMark approval "imminent," CEO tells Oppenheimer conference.
Executive Summary
ADVANCED MAGNETICS GASTROMARK APPROVAL IS "IMMINENT," CEO Jerome Goldstein told an Oppenheimer & Co. health care conference in New York City Oct. 30. NDA 20-410 for the oral gastrointestinal magnetic resonance imaging agent became "approvable" at FDA May 7 ("The Pink Sheet" July 22, In Brief). FDA refused to file Advanced Magnetics' original GastroMark NDA in 1992 for lack of a disease-specific indication; the same NDA, without a disease-specific indication, was resubmitted in November 1993.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth